

# Emanuel Della-Torre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6794175/publications.pdf>

Version: 2024-02-01

107  
papers

7,968  
citations

76326

40  
h-index

51608

86  
g-index

109  
all docs

109  
docs citations

109  
times ranked

8820  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia"™ by Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e158-e158.	0.9	10
2	Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: "Correspondence on: "Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation"™ an open-label cohort study"™ by Della-Torre et al"™ by Cheng and Zhang. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e197-e197.	0.9	5
3	Colchicine treatment in community healthcare setting to prevent severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e198-e198.	0.9	6
4	Dupilumab as a potential steroid-sparing treatment for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e24-e24.	0.9	7
5	Outcomes of noninvasive ventilation as the ceiling of treatment in patients with COVID-19. <i>Panminerva Medica</i> , 2022, 64, .	0.8	13
6	Lifetime Allergy Symptoms in IgG4-Related Disease: A Case-Control Study. <i>Arthritis Care and Research</i> , 2022, 74, 1188-1195.	3.4	13
7	Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. <i>Endoscopic Ultrasound</i> , 2022, 11, 216.	1.5	5
8	Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2022, 100, 83-93.	2.2	8
9	B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 867902.	4.8	8
10	Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study. <i>Nutrients</i> , 2022, 14, 1513.	4.1	13
11	Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. <i>Rheumatology</i> , 2022, 61, e109-e111.	1.9	4
12	Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
13	Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature. <i>United European Gastroenterology Journal</i> , 2022, 10, 496-506.	3.8	11
14	CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 368-382.	2.9	53
15	Urgent manifestations of immunoglobulin G <sub>4</sub> -related disease. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 48-51.	1.1	6
16	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	2.5	49
17	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021, 27, 451-457.	6.0	243
18	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. <i>European Journal of Internal Medicine</i> , 2021, 84, 63-67.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Emerging therapy options for IgG4-related disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 471-483.	3.0	20
20	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	3.9	140
21	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	4.8	35
22	Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease. <i>Rheumatology</i> , 2021, 60, 3947-3949.	1.9	7
23	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 522-532.	10.7	195
24	Correspondence on "Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort". <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e159-e159.	0.9	18
25	Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. <i>European Journal of Internal Medicine</i> , 2021, 87, 121-123.	2.2	3
26	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	1.1	20
27	Morphologic endoscopic ultrasound features in the differential diagnosis between type 1 focal autoimmune pancreatitis and pancreatic cancer. <i>Pancreatology</i> , 2021, 21, S87-S88.	1.1	0
28	The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 227-235.	1.7	2
29	Utility of the "2019 ACR/EULAR classification criteria" for the management of patients with IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 761-765.	3.4	6
30	Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1190-1192.	6.0	9
31	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. <i>Vaccine</i> , 2021, 39, 6464-6469.	3.8	8
32	OC.03.7 ENDOSCOPIC ULTRASOUND-GUIDED ABLATION WITH HYBRIDTHERM PROBE IN ADDITION TO CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR THE TREATMENT OF LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER: A PHASE II RANDOMIZED CONTROLLED TRIAL. <i>Digestive and Liver Disease</i> , 2021, 53, S104.	0.9	0
33	Serum IgG4 level predicts COVID-19 related mortality. <i>European Journal of Internal Medicine</i> , 2021, 93, 107-109.	2.2	21
34	AF.149 SIGNATURE ENDOSCOPIC ULTRASOUND FEATURES ARE HELPFUL IN THE DIFFERENTIAL DIAGNOSIS BETWEEN TYPE 1 FOCAL AUTOIMMUNE PANCREATITIS AND PANCREATIC CANCER: A PROOF-OF-CONCEPT STUDY. <i>Digestive and Liver Disease</i> , 2021, 53, S204.	0.9	0
35	Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. <i>Cancers</i> , 2021, 13, 4512.	3.7	7
36	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845.	3.2	14

#	ARTICLE	IF	CITATIONS
37	Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease. <i>Rheumatology</i> , 2021, 60, 4929-4941.	1.9	10
38	Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply. <i>European Journal of Internal Medicine</i> , 2021, , .	2.2	3
39	Treating Type 2 Autoimmune Pancreatitis With Colchicine: A Case Series. <i>Annals of Internal Medicine</i> , 2021, 174, 1775-1776.	3.9	6
40	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e829-e831.	3.9	13
41	B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 968-981.e14.	2.9	85
42	Colchicine as a new therapeutic option for antithyroid arthritis syndrome. <i>Rheumatology</i> , 2020, 59, 1452-1453.	1.9	6
43	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. <i>European Journal of Internal Medicine</i> , 2020, 74, 92-98.	2.2	52
44	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 77-87.	0.9	390
45	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	5.6	292
46	Systemic lupus erythematosus and COVID-19: what we know so far. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-218601.	0.9	12
47	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2020, 9, 1794359.	4.6	25
48	Mavrilimumab for severe COVID-19 " Authors' reply. <i>Lancet Rheumatology, The</i> , 2020, 2, e662-e663.	3.9	4
49	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e325-e331.	3.9	808
50	Treating COVID-19 with colchicine in community healthcare setting. <i>Clinical Immunology</i> , 2020, 217, 108490.	3.2	69
51	Sa1476 IMMUNOMODULATION INDUCED BY ENDOSCOPIC ULTRASOUND-GUIDED ABLATION WITH THE HYBRIDTHERM PROBE IN STAGE III PANCREATIC DUCTAL ADENOCARCINOMA: SINGLE-CENTER PRELIMINARY RESULTS FROM A PHASE II/III RANDOMIZED-CONTROLLED TRIAL. <i>Gastrointestinal Endoscopy</i> , 2020, 91, AB207-AB208.	1.0	0
52	Advances in the diagnosis and management of IgG4 related disease. <i>BMJ, The</i> , 2020, 369, m1067.	6.0	140
53	European Guideline on IgG4-related digestive disease " UEG and SGF evidence-based recommendations. <i>United European Gastroenterology Journal</i> , 2020, 8, 637-666.	3.8	120
54	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e465-e473.	3.9	173

#	ARTICLE	IF	CITATIONS
55	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020, 59, 2435-2442.	1.9	46
56	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1150-1157.	3.4	52
57	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
58	IgG4-related disease and allergen-specific immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 631-633.	1.0	9
59	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	2.2	349
60	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. <i>Endoscopy International Open</i> , 2020, 08, E1511-E1519.	1.8	6
61	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
62	IgG4-related autoimmune liver disease. <i>Minerva Gastroenterology</i> , 2020, , .	0.5	1
63	Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 736-745.e6.	2.9	123
64	OP0167â€¦B LYMPHOCYTES DIRECTLY CONTRIBUTE TO TISSUE FIBROSIS IN IGG4-RELATED DISEASE. , 2019, , .		1
65	FRI0584â€¦EFFICACY AND SAFETY OF RITUXIMAB FOR INDUCTION OF REMISSION AND MAINTENANCE OF IGG4-RELATED DISEASE: EXPERIENCE FROM AN ITALIAN NATIONAL REFERRAL CENTRE. , 2019, , .		0
66	FRI0587â€¦IGG4-RELATED DISEASE IN ITALY: RESULTS FROM A MONOCENTRIC COHORT OF 150 PATIENTS (2013â€“2018). , 2019, , .		0
67	Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 831-833.	0.4	13
68	Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 159-166.	0.8	13
69	An International Multispecialty Validation Study of the IgG4â€Related Disease Responder Index. <i>Arthritis Care and Research</i> , 2018, 70, 1671-1678.	3.4	103
70	A <scp>CD</scp>8Î±â€ Subset of <scp>CD</scp>4+<scp>SLAMF</scp>7+ Cytotoxic T Cells Is Expanded in Patients With IgG4â€Related Disease and Decreases Following Glucocorticoid Treatment. <i>Arthritis and Rheumatology</i> , 2018, 70, 1133-1143.	5.6	87
71	Intrathecal rituximab for IgG<sub>4</sub>-related hypertrophic pachymeningitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 441-444.	1.9	30
72	IgG4â€related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach. <i>Apmis</i> , 2018, 126, 459-476.	2.0	95

#	ARTICLE	IF	CITATIONS
73	Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. <i>Arthritis Research and Therapy</i> , 2018, 20, 222.	3.5	41
74	Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 276-279.	1.9	12
75	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017, 56, 2084-2092.	1.9	60
76	Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. <i>Modern Rheumatology</i> , 2017, 27, 638-645.	1.8	28
77	Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis. <i>Acta Otorhinolaryngologica Italica</i> , 2017, 37, 281-285.	1.5	35
78	Roles of Plasmablasts and B Cells in IgG4-Related Disease: Implications for Therapy and Early Treatment Outcomes. <i>Current Topics in Microbiology and Immunology</i> , 2016, 401, 85-92.	1.1	23
79	â€œHow I manageâ€IgG4-Related Disease. <i>Journal of Clinical Immunology</i> , 2016, 36, 754-763.	3.8	40
80	Juxta-vertebral lesions in granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 356-360.	3.4	11
81	Antineutrophil cytoplasmic antibody positivity in IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e4633.	1.0	69
82	Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 825-838.	2.9	306
83	IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 135-145.	1.1	106
84	Plasmablasts: A Promising Biomarker in IgG4-Related Disease. , 2016, , 65-72.		0
85	Immunology of IgG4-related disease. <i>Clinical and Experimental Immunology</i> , 2015, 181, 191-206.	2.6	170
86	Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?. <i>Clinical and Molecular Allergy</i> , 2015, 13, 23.	1.8	14
87	Methotrexate for maintenance of remission in IgG4-related disease: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1934-1936.	1.9	54
88	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2236-2243.	0.9	120
89	International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2015, 67, 1688-1699.	5.6	767
90	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 190-195.	0.9	409

#	ARTICLE	IF	CITATIONS
91	Clinical Manifestations of IgG4-Related Disease in the Pharynx. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2015, 124, 173-178.	1.1	31
92	Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 399-402.	5.7	109
93	IgG4-Related Hypertrophic Pachymeningitis. <i>JAMA Neurology</i> , 2014, 71, 785.	9.0	198
94	IgG4-Related Disease and Other Causes of Inflammatory Meningeal Disease. <i>Seminars in Neurology</i> , 2014, 34, 395-404.	1.4	9
95	Diagnostic value of IgG4 Indices in IgG4-Related Hypertrophic Pachymeningitis. <i>Journal of Neuroimmunology</i> , 2014, 266, 82-86.	2.3	61
96	Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 269-272.	5.7	240
97	IgG4-related midline destructive lesion. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1434-1436.	0.9	43
98	De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 679-687.	2.9	302
99	Optimal management of DRESS syndrome in course of infectious endocarditis. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 303-305.	1.0	9
100	InÂvivo tests with â€œTahiniâ€•sauce: new allergenic source to evaluate IgE-mediated hypersensitivity to sesame. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 209-210.	1.0	17
101	Cerebrospinal Fluid Analysis in Immunoglobulin G4-related Hypertrophic Pachymeningitis. <i>Journal of Rheumatology</i> , 2013, 40, 1927-1929.	2.0	42
102	IgG4-Related Pachymeningitis: Evidence of Intrathecal IgG4 on Cerebrospinal Fluid Analysis. <i>Annals of Internal Medicine</i> , 2012, 156, 401.	3.9	47
103	Atypical presentation of Churg-Strauss syndrome or an undescribed hypereosinophilic disease?. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 908-911.	2.9	0
104	Erdheim-Chester Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 704-706.	1.3	8
105	Causes of Food-Induced Anaphylaxis in Italian Adults: A Multi-Centre Study. <i>International Archives of Allergy and Immunology</i> , 2009, 150, 271-277.	2.1	118
106	EpidemAAITO: Features of food allergy in Italian adults attending allergy clinics: a multiâ€•centre study. <i>Clinical and Experimental Allergy</i> , 2009, 39, 547-555.	2.9	108
107	Sildenafil in pulmonary hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005, 22, 78-9.	0.2	5